Metronomic Oral Vinorelbine Plus Anti-PD-L1/Anti-CTLA4 ImmunothErapy in Patients With Advanced Solid Tumours

Conditions:   Advanced Solid Tumours;   Breast Cancer;   Head and Neck Cancer;   Cervix Cancer;   Prostate Cancer
Intervention:   Drug: Durvalumab + Tremelimumab + metronomic Vinorelbine
Sponsors:   UNICANCER;   National Cancer Institute, France;   AstraZeneca;   Pierre Fabre Laboratories
Not yet recruiting

https://ift.tt/2FTSwYt